SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves better-than-expected quarterly results, raised outlook and growing AI-compute backlog have shifted attention toward strong demand and managements plan to fund expansion with customer prepayments and contract-backed financing. Many traders see the call as easing debt concerns and anticipate short covering, while skeptics remain focused on heavy borrowing, capital spending and the path to sustainable cash flow.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is dominated by concern over the investigation into CEO Jensen Huangs reported relationship with a woman suspected of ties to Chinese intelligence, and whether it raises governance, national-security or leadership risks. Traders are divided between viewing the situation as a serious threat to confidence and treating it as noise or an oversold dip, with some looking for a rebound.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and earnings call dominate discussion, with traders weighing improved profitability, margins and cash from Samsung licensing against the gap between reported results and some elevated estimates, as well as weaker sequential product sales. Many are bullish on recurring Samsung and Micron licensing revenue and growth plans, while a possible SK Hynix deal and Nasdaq uplisting remain speculation rather than confirmed developments.

Autonomi (ANT) is a cryptocurrency launched in 2025and operates on the Arbitrum platform. Autonomi has a current supply of 1,200,000,000 with 346,011,579 in circulation. The last known price of Autonomi is 0.03102024 USD and is up 12.83 over the last 24 hours. It is currently trading on 15 active market(s) with $148,822.58 traded over the last 24 hours. More information can be found at https://autonomi.com.

Aragon

The ticker is being confused with Anthropics heavily discussed IPO, while Aragon-specific posts focus on the projects dissolution, completed ANT redemption, and questions about token delisting or conversion. Crypto traders also mention the tokens price move, but no clear new Aragon catalyst dominates.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNavs Q3 report, which traders say beat EPS expectations, is drawing attention as shares fell despite a generally positive reaction to the results and call. The debate remains split between near-term sellers and bulls focused on the still-pending FCC NPRM for the companys spectrum proposal.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

INFQ is drawing attention ahead of its quarterly report, with traders looking for revenue, guidance and commercialization updates that could set it apart from other quantum companies. Optimism about its products and technical progress is countered by concerns over weak price action and volatility alongside the broader quantum and tech sectors.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zetas strong quarterly earnings beat and raised guidance have driven attention, with traders citing accelerating growth, improving profitability and analyst upgrades as support for the rally. The reaction is split between bulls expecting momentum to continue and skeptics focused on volatile post-earnings trading and resistance near recent levels.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroups quarterly earnings beat expectations, but the shares faced selling despite the strong report. Traders are debating whether higher expenses and credit-loss provisions in the card business outweigh growth elsewhere, while some view the pullback as a buying opportunity near technical support.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos steep correction is dominating discussion, with traders sharing bearish technical outlooks and speculating that large funds are selling; those selling claims are unconfirmed. The decline has fueled debate over whether uranium stocks are being repriced amid doubts about the timing of AI-related power demand, or whether the pullback is an opportunity given the sectors longer-term nuclear outlook.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuums reported quantum error-correction advances and federal CHIPS research funding are fueling interest, alongside its Oracle and NVIDIA ties. Traders are split between optimism about the companys technology and concerns over valuation, future share supply and limited near-term revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results

ARS Pharma missed Q3 earnings and sales estimates; shares rose 5.6% premarket as analysts cut price targets despite neffy progress.read more...

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -5.88% and -11.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("ARS Pharmaceuticals or the Company) (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities...

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYPR NewswireNEW YORK, Oct. 5, 2026NEW YORK, Oct. 5, 2026...

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 5, 2026LOS ANGELES, Oct. 5, 2026 /PRNewswire/ -- Schall, Brown...

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct. 2, 2026NEW YORK, Oct. 2, 2026...

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026PR...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRYPR NewswireNEW YORK, Sept. 30, 2026Wall...

SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Sept. 28, 2026 NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Why:Rosen...

• Reported GAAP EPS of -$0.36 up 30.77% YoY
• Reported revenue of $37.71M up 16.03% YoY
• ARS Pharmaceuticals' second-half 2026 aggregate SG&A and R&D guidance is $114M to $126M, including stock-based compensation; ARS continues to expect cash flow breakeven by the end of 2027.

ARS Pharmaceuticals reported $71.9M in third-quarter operating expenses, $18.3M in R&D versus $2.8M a year earlier, and risks involving coverage and neffy market acceptance.

ARS Pharmaceuticals grew neffy revenue and U.S. market share, advanced ARS-2 toward Phase 2b data, and reported lower SG&A expenses alongside its cash-flow-breakeven target for year-end 2027.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>ARS Pharmaceuticals shares tumbled after the company said Neffy failed to secure expanded commercial insurance coverage for the July 1 review cycle.&nbsp;</li><li>Passage Bio shares fell after the company agreed to merge with Remix Therapeutics in an all-stock deal.</li><li>Boxlight shares dropped after hours following a speculative rally fueled by the company's recent 1-for-6 reverse stock split.&nbsp;</li></ul>ARS Pharmaceuticals (SPRY), Passage Bio (PASG), and Boxlight Corp. (BOXL),&nbsp;all small-cap stocks, posted double-digit losses in after-hours trading on Wednesday as investors digested new business developments.<h2 class="st-heading-2">SPRY Faces Coverage Setback</h2>ARS Pharmaceuticals shares came under heavy selling after investors reacted to an <a href="https://stocktwits.com/news-articles/markets/equity/spry-stock-tanks-after-hours-ars-pharmaceuticals-reports-no-new-major-insurance-wins-for-neffy/cZK6ySGR7Q4">update</a> on insurance coverage for Neffy, the company's needle-free treatment for severe allergic reactions.&nbsp;The stock fell after the company said talks with health insurers did not lead to broader coverage for the July 1 review cycle. Investors saw the setback as a challenge to sales growth and increased product use.&nbsp;Commercial insurance support often plays a major role in determining how quickly newly approved therapies gain traction. Additionally, the company lowered its projected 2026 cash-based operating expense forecast to approximately $248 million.&nbsp;<a href="https://stocktwits.com/symbol/SPRY">ARS Pharmaceuticals’ stock</a> traded over 24% lower overnight. On Stocktwits, retail sentiment around the stock&nbsp;improved to ‘neutral’ from ‘bearish’ the previous day.&nbsp;<h2 class="st-heading-2">PASG Drops Following Deal Announcement</h2>Passage Bio declined after unveiling a <a href="https://stocktwits.com/news-articles/markets/equity/pasg-stock-slumps-after-hours-whats-driving-the-selloff/cZKyoZ4R7Q5">merger</a> agreement involving Remix Therapeutics, Inc. The companies have agreed to combine through an all-stock transaction that will create a publicly traded biotechnology company focused on RNA-processing therapies.&nbsp;The merged business plans to operate as Remix Therapeutics and list its shares on Nasdaq under the ticker symbol RMTX following the completion of the deal with existing Passage Bio shareholders expected to own roughly 7% of the combined entity.&nbsp;The transaction is accompanied by an oversubscribed private financing expected to generate approximately $100 million in gross proceeds from a group of investors led by Decheng Capital.<a href="https://stocktwits.com/symbol/PASG">Passage Bio stock</a> traded over 15% lower overnight. Retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">Post-Split Volatility Drives Sharp Reversal In BOXL After Massive Rally&nbsp;</h2>Boxlight shares pulled back in after-hours trading after jumping 37% during the regular session. The education technology company, which recently&nbsp;completed a reverse stock split to remain listed on Nasdaq, saw investors take profits after a surge driven by heavy speculative buying.&nbsp;The decline followed a daytime surge that pushed shares significantly higher before momentum faded. Traders appeared to reassess positions after a rapid advance fueled by heavy volume and a reduced share count.On Monday, Boxlight implemented a 1-for-6 reverse stock split, which reduced the number of authorized Class A shares, creating a much tighter trading float and increasing the stock’s sensitivity to buying and selling activity.<a href="https://stocktwits.com/symbol/BOXL">Boxlight stock</a> traded over 17% lower overnight. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day.&nbsp;So far this year, PASG and BOXL stocks have plunged 50% and 52%, respectively, while SPRY stock has declined 9%.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pfe-stock-continues-to-drop-as-lung-cancer-trial-disappointment-overshadows-ibrance-win/cZKyn58R7Qc">PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

ARS Pharmaceuticals (SPRY), Passage Bio (PASG), and Boxlight Corp. (BOXL),&nbsp;all small-cap stocks, posted double-digit losses in after-hours trading on Wednesday as investors digested new business developments.

The after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans. 


Boxlight Corp

Passage Bio Inc

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Current Price	$3.57
Prev Close	$3.15
Open	$3.15
Dividend Yield	0.00%
50-Day Moving Average	$4.19
Beta	1.29
Avg. Volume	1.67M
PE Ratio	-1.77

52-Week High	$13.15
52-Week Low	$2.44
Market Capitalization	$316.66M
EPS (Annual)	-$1.74
Price to Book	-29.94
Revenue Per Employee	$517,042.95

Feed

News

Sentiment

Earnings

Fundamentals

Info

SPRY Fundamentals